Jazz Pharmaceuticals ((JAZZ)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jazz Pharmaceuticals is conducting a Phase 3 study titled A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician’s Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer. The study aims to evaluate the efficacy and safety of zanidatamab combined with chemotherapy compared to trastuzumab combined with chemotherapy in patients with metastatic HER2-positive breast cancer who have not responded to previous treatments.
The study tests zanidatamab, an experimental drug administered intravenously, against trastuzumab, a standard treatment, both combined with a physician’s choice of chemotherapy options like eribulin, vinorelbine, gemcitabine, or capecitabine. The goal is to determine if zanidatamab offers a better treatment alternative.
This interventional study uses a randomized, parallel assignment model without masking, focusing on treatment efficacy. Participants are assigned to either the zanidatamab or trastuzumab group, with the primary objective of assessing treatment effectiveness.
The study began on August 13, 2024, with a recent update on July 14, 2025. These dates are crucial as they mark the study’s progress and the latest data collection.
The outcome of this study could significantly impact Jazz Pharmaceuticals’ market position, potentially boosting its stock if zanidatamab proves more effective. This could also influence the competitive landscape in HER2-positive breast cancer treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.